ANDA 62563, held by Elkins Sinn. Erythromycin Lactobionate.
As of Nov 16, 2026, ANDA 62563 (Erythromycin), held by Elkins Sinn, was first approved by FDA on Mar 28, 1985, with 10 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 28, 1985 | Original application | Approved | None posted |
| ErythromycinEQ 500MG BASE/VIAL · injectable;injection | Erythromycin Lactobionate | Discontinued |
| ErythromycinEQ 1GM BASE/VIAL · injectable;injection | Erythromycin Lactobionate | Discontinued |
| Mar 1, 1996 | Supplement 22Labeling | Approved | None posted |
| Sep 18, 1995 | Supplement 21Manufacturing | Approved | None posted |
| Aug 18, 1994 | Supplement 18Manufacturing | Approved | None posted |
| Mar 23, 1994 | Supplement 19Manufacturing | Approved | None posted |
| Oct 22, 1993 | Supplement 17Manufacturing | Approved | None posted |
| Mar 1, 1993 | Supplement 16Labeling | Approved | None posted |
| Apr 22, 1992 | Supplement 15Labeling | Approved | None posted |
| Mar 18, 1992 | Supplement 14Manufacturing | Approved | None posted |
| Sep 16, 1991 | Supplement 13Labeling | Approved | None posted |
| Aug 27, 1990 | Supplement 12Manufacturing | Approved | None posted |
| Mar 28, 1985 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters